Integrant announces closure of Series A capital raise. Now exploring pre-IPO raise ahead of November listing

SYDNEY–(BUSINESS WIRE)–#AI–Integrant (proposed ticker: INGT) today announced the successful closure of its Series A capital raise, originally opened in April 2025. The round attracted strong investor interest, with responses described by the company as highly encouraging and reflective of growing confidence in its technology and strategic direction.

Integrant Logo Black Background
Integrant Logo Black Background

Since initiating the Series A, Integrant has achieved a series of technical milestones, including meaningful progress in the development of its artificial intelligence platform. Considering both the capital secured and these advancements, the company has reassessed its funding strategy. Management has determined that the original allocation framework established at the outset of the Series A is no longer aligned with current priorities and opportunities.

With the company currently targeting an initial public offering (IPO) in approximately seven months, Integrant is actively exploring a pre-IPO placement. This prospective round is intended to provide an opportunity for investors who were unable to participate in the Series A to engage with the company ahead of a potential public listing.

The pre-IPO raise is expected to support final-stage development, operational scaling, and market readiness initiatives as Integrant continues preparations for its targeted Nasdaq listing.

Investors seeking further information regarding the anticipated IPO or pre-IPO participation are encouraged to make direct contact with the company.

About Integrant

Integrant is a technology company developing integrated solutions across artificial intelligence, medical technology and biologics.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the proposed IPO and future fundraising activities. These statements are subject to risks and uncertainties, and actual results may differ materially. Integrant undertakes no obligation to update forward-looking statements, except as required by applicable law.

Contacts

Media Contact:
Adelaide Slater

Integrant Pty Ltd

Phone: +61 439 880 233

Email: [email protected]
Website: www.integrant.com.au
Investment Contact:
Email: [email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.